- Walgreens puts its money where its mouth is with World AIDS Day campaign
- Walgreens launches high-impact push in support of World AIDS Day campaign
- Moving PSE to Rx-only in Mo. lacks fiscal sense
- Gallup: Take Care Clinics top in customer service
- Bartell to cease filling Medicaid prescriptions at 15 locations
TORONTO Drug makers Valeant Pharmaceuticals International and Kadmon Pharmaceuticals will collaborate to develop antiviral drugs for treating such diseases as hepatitis C, the two companies said Monday.
Kadmon, founded by former ImClone Systems chief executive Samuel Waksal, will pay Valeant $5 million upfront, plus milestones and royalties, for the right to develop taribavirin. Under a separate agreement, Valeant paid Kadmon $7.5 million to market ribavirin, also a hepatitis C drug, in several European countries.
“We are pleased to find a strong partner for a compound that we believe has potential to help patients in need of improved treatment,” Valeant CEO J. Michael Pearson stated. “While participating in product development in the overall hepatitis C market no longer fits within our corporate development strategy, ribavirin should be a significant product for our branded generics portfolio in central Europe.”